19.90
-0.66(-3.21%)
Currency In USD
| Previous Close | 20.56 |
| Open | 20.66 |
| Day High | 20.8 |
| Day Low | 19.81 |
| 52-Week High | 35.84 |
| 52-Week Low | 14.59 |
| Volume | 349,927 |
| Average Volume | 505,409 |
| Market Cap | 577.27M |
| PE | -58.53 |
| EPS | -0.34 |
| Moving Average 50 Days | 18.54 |
| Moving Average 200 Days | 22.93 |
| Change | -0.66 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $929.91 as of August 20, 2025 at a share price of $19.9. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $437.17 as of August 20, 2025 at a share price of $19.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Jul 29, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a comp
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
GlobeNewswire Inc.
Jul 25, 2025 11:00 AM GMT
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations FRIENDSWOOD, Texas, July 25, 2025
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
GlobeNewswire Inc.
Jul 23, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthro